Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Cytokinetics, Inc. at the 30th Annual Piper Jaffray Healthcare Conference
    Nov 27, 2018 10:00 AM EST

    Cytokinetics, Inc. at the 30th Annual Piper Jaffray Healthcare Conference
    Nov 27, 2018 10:00 AM EST
  • Webcast Image Webcast
    X Cytokinetics, Inc. at the Credit Suisse 27th Annual Healthcare Conference
    Nov 13, 2018 10:20 AM MST

    Cytokinetics, Inc. at the Credit Suisse 27th Annual Healthcare Conference
    Nov 13, 2018 10:20 AM MST
  • Webcast Image Webcast
    X Q3 2018 Cytokinetics, Inc. Earnings Conference Call
    Nov 1, 2018 4:30 PM EDT

    Q3 2018 Cytokinetics, Inc. Earnings Conference Call
    Nov 1, 2018 4:30 PM EDT
  • Webcast Image Webcast
    X Cytokinetics 2018 R&D Day
    Oct 16, 2018 8:30 AM EDT

    Cytokinetics 2018 R&D Day
    Oct 16, 2018 8:30 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

Annual Report image Annual Report & Stockholder Meeting Materials and Information

2018 Letter from the CEO

ANNUAL REPORT

READ MORE

CORPORATE PRESENTATION

READ MORE

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
Company 1.3 MB
ALS

ALS

07/13/18
( FY )
ALS 353.6 KB
SMA

SMA

07/13/18
( FY )
SMA 287 KB

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday,
Toggle Summary Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results
METEORIC-HF Advancing to Trial Initiation FORTITUDE-ALS on Track to Complete Enrollment by Year End Phase 1 Clinical Studies of CK-274 and AMG 594 To Start in Q4 SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for
Toggle Summary Cytokinetics to Announce Third Quarter Results on November 1, 2018
SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day
Investigational New Drug Applications Recently Filed for Two New Cardiac Programs: Cardiac Troponin Activator and Cardiac Myosin Inhibitor Advance Toward Phase 1 Studies Clinical Trial Design Announced for METEORIC-HF,  the Second Phase 3 Trial of Omecamtiv Mecarbil Phase 2 Clinical Trial of
READ MORE

EVENTS

READ MORE